0.03
—
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Microba Life Sciences
Its shares trade on ASX under the ticker MAP.AX. It has been listed since 5 April 2022. In the fiscal year to 30 June 2025, it reported revenue of A$15.7m and a net loss of A$14.9m. At that date it held total assets of A$47.4m and shareholders' equity of A$32.5m.
Microba Life Sciences Ltd. analyzes the microbiome to discover novel therapeutics and develop new diagnostic tools. The company is headquartered in Brisbane, Queensland. The company went IPO on 2022-04-05. The firm is engaged in the discovery and development of therapeutics for major chronic diseases and delivers gut microbiome testing services globally to researchers, clinicians and consumers. The company offers a range of platforms, such as Analysis Platform, Discovery Platform and Therapeutic Platform. Through its analysis and discovery platforms, it identifies microbiome-derived therapeutics and diagnostic tools to advance medicine. The company provides precise and comprehensive measurements of the human gut microbiome. Through its Analysis Platform, it generates a global databank of microbiome samples and associated metadata to develop new health solutions. Its Discovery Platform enables partners to access this databank for the data-driven discovery of product opportunities. Its therapeutic platform is a repeatable platform for microbial therapeutic leads. The company has two segments: Testing Services, and Research & Development.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 5 Apr 2022
- Website
- microba.com ↗
Leadership
Pay as last reported
- Mr. Pasquale RombolaNon-Executive Independent Chairman of the board, since 2017A$53,232
- Dr. Luke ReidChief Executive OfficerA$406,835
- Prof. Ian FrazerNon-Executive Independent Deputy Chairman of the board, since 2017A$48,232
- Mr. James HeathChief Financial Officer, Company SecretaryA$278,150
- Mr. Richard BundNon-Executive DirectorA$37,553
- Dr. Hyungtae KimNon-Executive DirectorA$31,359
- Prof. Gene TysonNon-Executive Director, Co-founderA$84,390
- Ms. Jacqueline FernleyIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Microba Life Sciences Ltd. offers a comprehensive Analysis Platform for global microbiome data collection.
- The company's Discovery Platform provides partners with access to a global microbiome databank for data-driven opportunities.
- Microba's Therapeutic Platform enables repeatable development of microbial therapeutic leads.
Weaknesses
- Microba Life Sciences Ltd. is headquartered in Brisbane, Queensland, which may limit global market access.
- The company's IPO on 5 April 2022 indicates a relatively recent market entry.
- Microba's business model relies heavily on the Health Care sector's regulatory environment.
Opportunities
- Microba Life Sciences Ltd. can expand its Testing Services segment to new global markets beyond current reach.
- The company's Research & Development segment has potential for new therapeutic discoveries in chronic diseases.
- Microba's platforms can integrate with emerging Health Care technologies for enhanced solutions.
Threats
- Microba Life Sciences Ltd. faces competition from established players in the Health Care sector.
- The company's reliance on the Health Care industry exposes it to regulatory changes and market volatility.
- Microba's IPO timing in 2022 may coincide with economic downturns affecting investor confidence.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.